AI Article Synopsis
- * This study analyzed the activity of 10 key CYP3A reactions in both humans and dogs, confirming that most reactions are primarily driven by CYP3A12 in dogs and CYP3A in humans, with some reactions also involving the CYP2B11 enzyme in dogs.
- * The findings clarify the differences in CYP3A activity between humans and dogs, suggesting that this knowledge could enhance drug metabolism research and evaluation of drug interactions in both species.
Article Abstract
Cytochrome P450 3A (CYP3A), the most important class of drug-metabolizing enzymes, participates in the metabolism of half of clinically used drugs. The CYP3A index reactions of dogs, one of the most widely used preclinical nonrodent species, are still poorly understood. This work evaluated the activity and selectivity of 10 CYP3A index reactions, including midazolam (MDZ) 1'- and 4-hydroxylation, alprazolam (APZ) and triazolam (TRZ) - and 4-hydroxylation, testosterone (T) 6-hydroxylation, lithocholate (LCA) 6-hydroxylation, deoxycholate (DCA) 1- and 5-hydroxylation, with quantitative reaction phenotyping and kinetic analysis in human and canine recombinant CYP enzymes (rCYPs). In human studies, all reactions are reconfirmed as mixed index reactions of CYP3A with minor contributions from non-CYP3A isoforms. In canine studies, all reactions are also primarily catalyzed by CYP3A12 with lower contributions from CYP3A26. However, the canine CYP2B11 appreciably contributes to the hydroxylation of benzodiazepines except for APZ 4-hydroxylation. The canine CYP3A isoforms have lower activity than human isoforms toward T 6-hydroxylation and LCA 6-hydroxylation and both substrates undergo non-CYP3A catalyzed side reactions. DCA 1- and 5-hydroxylation are validated as the CYP3A index reactions in both humans and dogs with limited non-CYP3A contributions and side reactions. In conclusion, this work provides a comprehensive overview for the selectivity and activity of in vitro CYP3A index reactions in humans and dogs. The validated CYP3A index reactions between humans and dogs may benefit future practices in drug metabolism and drug interaction studies. SIGNIFICANCE STATEMENT: Dogs are one of the most important nonrodent animals with limited studies of cytochrome P450 enzymes than humans. This work provides the most comprehensive quantitative data to date for the selectivity and activity of CYP3A index reactions in humans and dogs. The canine CYP2B11 was found to appreciably contribute to hydroxylation of midazolam, alprazolam and triazolam, the well-known probes for human CYP3A. Deoxycholate 1- and 5-hydroxylation are validated as the CYP3A index reactions in both humans and dogs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1124/dmd.122.000864 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A novel approach to monitoring Cyp3a induction and inhibition by bioluminescent urinalysis.
Expert Opin Drug Metab Toxicol
November 2024
Research and Development Department, Promega Corporation, Madison, WI, USA.
Background: Adverse drug-drug interactions (DDI) may occur when one drug accelerates or slows a second drug's metabolism by, respectively, inducing or inhibiting a cytochrome P450 (CYP) that metabolizes that second drug. We developed an method employing urinalysis to complement CYP induction and inhibition measurements widely used to predict DDIs.
Research Design And Methods: Focusing on Cyp3a enzymes, the major mammalian drug metabolizers, we applied luciferin-IPA, a selective Cyp3a probe substrate to mice after Cyp3a inducers and inhibitor treatments.
Expert Opinion on Managing Adverse Reactions Associated With Acalabrutinib Therapy: A Delphi Consensus From France.
Clin Lymphoma Myeloma Leuk
October 2024
Department of Pharmacy, Paris Public Hospital at Home (HAD AP-HP), University Hospitals of Paris, Paris, France.
Article Synopsis
- - Acalabrutinib, a more advanced treatment for chronic lymphocytic leukemia, has a better safety profile than older drugs but lacks clear guidelines on managing its side effects, prompting a study to establish best practices.
- - A team of medical professionals across France found that hospital pharmacists should evaluate drug interactions before starting patients on acalabrutinib and advised against using it with certain medications that can increase risks of toxicity or reduce effectiveness.
- - The study highlighted the need for monitoring blood pressure during treatment, outlined protocols for managing procedures, and suggested headache management strategies, demonstrating the importance of teamwork in improving patient care while using acalabrutinib.
Effect of CYP3A5*3 genotype on exposure and efficacy of quetiapine: A retrospective, cohort study.
J Affect Disord
February 2025
Department of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, China; The Technology Innovation Center for Artificial Intelligence in Clinical Pharmacy of Hebei Province, The First Hospital of Hebei Medical University, Shijiazhuang, China. Electronic address:
Background: The involvement of cytochrome P450 3A5 (CYP3A5) in the metabolism of quetiapine has been proposed, though conclusive evidence is lacking. This study aimed to quantitatively assess the impact of CYP3A5 genetic variability on quetiapine exposure in a Chinese patient population.
Methods: Patient data were retrospectively collected from the database of the Mental Health Centre at the First Hospital of Hebei Medical University, covering the period from September 1, 2019, to July 1, 2023.
Detection and Quantification of Drug-Protein Adducts in Human Liver.
J Proteome Res
November 2024
Institute for Systems Biology, Seattle, Washington 98109, United States.
Article Synopsis
- This study identifies the formation of covalent protein adducts from drug metabolism as significant risk factors for adverse drug reactions and cytochrome P450 enzyme inactivation.
- It introduces a novel liquid chromatography with tandem mass spectrometry (LC-MS/MS) approach to detect low abundance drug-protein adducts in human liver microsomes, using raloxifene as a model.
- The findings reveal adducts in multiple proteins, including CYP enzymes, and suggest that some adducts may be harmless, providing a framework for better understanding the human adductome related to drug exposure.
Prediction of Pharmacokinetic Drug-Drug Interactions Involving Anlotinib as a Victim by Using Physiologically Based Pharmacokinetic Modeling.
Drug Des Devel Ther
October 2024
Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, People's Republic of China.
Background: Anlotinib was approved as a third line therapy for advanced non-small cell lung cancer in China. However, the impact of concurrent administration of various clinical drugs on the drug-drug interaction (DDI) potential of anlotinib remains undetermined. As such, this study aims to evaluate the DDI of anlotinib as a victim by establishing a physiologically based pharmacokinetic (PBPK) model.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!